Edoxaban shows Phase III benefits in knee surgery setting
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has released further details of a Phase III study in which its novel oral anticoagulant edoxaban showed benefits over exoxaparin in the prevention of venous thromboembolic (VTE) events in patients undergoing total knee replacement surgery.